-

01:00:15 PM

RVNC Stock News

RVNC - Revance Therapeutics Inc

09/19/23 9:00 AM

Nasdaq : RVNC

Revance Provides Corporate Update at Investor Day

Real-world feedback reinforces DAXXIFY’ s differentiated performance profile and continued opportunity for long-term, broad-based adoption. New pricing program for DAXXIFY ®, which became effective September 1, 2023, positions the product to be priced competitively to Botox ® Cosmetic for the provider, to further accelerate market share expansion....

RHEA-AI

neutral

08/22/23 8:00 AM

Nasdaq : RVNC

conferences

Revance to Host Investor Day on September 19, 2023

Revance’ s portfolio includes DAXXIFY ® for injection, the RHA ® Collection of dermal fillers in the U.S., and value-added services including the OPUL ® Relational Commerce platform for aesthetic practices. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to...

RHEA-AI

neutral

08/14/23 8:00 AM

Nasdaq : RVNC

fda approval

U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

Revance Therapeutics, Inc. today announced that the United States Food and Drug Administration has approved the first therapeutic indication for DAXXIFY ® for injection for the treatment of cervical dystonia in adults. 7 DAXXIFY ®, powered by Peptide Exchange Technology™, was previously approved by the FDA for the temporary improvement of glabellar...

RHEA-AI

neutral

08/08/23 4:05 PM

Nasdaq : RVNC

earnings

Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update

Revenue for the six months ended June 30, 2023 was $107.5 million compared to $53.6 million for the same period in 2022. Selling, general and administrative expenses for the three and six months ended June 30, 2023 were $77.4 million and $143.4 million compared to $47.8 million and $92.9 million, respectively, for the same periods in 2022, presented in...

RHEA-AI

neutral

08/01/23 8:00 AM

Nasdaq : RVNC

earnings

Revance to Release Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

Revance Therapeutics, Inc., today announced that the company will release second quarter 2023 financial results on Tuesday, August 8, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT/ 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in...

RHEA-AI

neutral

05/23/23 4:05 PM

Nasdaq : RVNC

conferences

Revance to Participate in Upcoming Investor Conferences

Revance Therapeutics, Inc. today announced that the company will be participating in the following investor conferences. Chief Executive Officer Mark J. Foley is scheduled to participate in a fireside chat on Tuesday, June 6, 2023, at 4:00 P.M. CDT, in Chicago, Illinois. Chief Executive Officer Mark J. Foley and President Dustin S. Sjuts are scheduled to...

RHEA-AI

neutral

05/09/23 4:05 PM

Nasdaq : RVNC

earnings

Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update

Revenue for the first quarter included $30.3 million of RHA ® Collection revenue, $15.4 million of DAXXIFY ® revenue, $3.6 million of service revenue and $0.1 million of collaboration revenue. Selling, general and administrative expenses for the first quarter ended March 31, 2023 were $66.0 million compared to $45.1 million for the same period in 2022,...

RHEA-AI

neutral

05/02/23 8:00 AM

Nasdaq : RVNC

earnings

Revance to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023

Revance Therapeutics, Inc., today announced that the company will release first quarter 2023 financial results on Tuesday, May 9, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT/ 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in...

RHEA-AI

neutral

04/05/23 8:00 AM

Nasdaq : RVNC

conferences

Revance to Participate in the Needham 22nd Annual Healthcare Conference

Revance Therapeutics, Inc., today announced that the company will participate in the 22 nd Annual Needham Virtual Healthcare Conference, taking place April 17– 20, 2023. Chief Financial Officer, Tobin Schilke, is scheduled to participate in a fireside chat on Tuesday, April 18, at 12:45 P.M. ET. Revance is headquartered in Nashville, Tennessee, with additional...

RHEA-AI

neutral

03/30/23 8:00 AM

Nasdaq : RVNC

Revance Publishes its 2022 Environmental, Social, and Governance (ESG) Report

Revance Therapeutics, Inc., today announced the release of its 2022 ESG Report, detailing the company’ s progress towards its ESG priorities of innovation and access, workplace culture and strong corporate governance. The report was guided by the Sustainability Accounting Standards Board framework. Our first product approval underscores our commitment to...

RHEA-AI

very positive

1 2 3 4 5 6 7 8 9 10 Next

RVNC Data

IndustryPharmaceutical Preparation Manufacturing
Websitehttp://www.revance.com/
Security nameRevance Therapeutics Inc
SectorManufacturing
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Pharmaceutical Preparation Manufacturing
CountryUnited States

About Revance Therapeutics Inc

revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form